Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
Balakrishnan, M., George, R., Sharma, A. & Graham, D. Y. Changing trends in stomach cancer throughout the world. Curr. Gastroenterol. Rep. 19, 36 (2017).
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Gastric Cancer, Version 2. (2022). https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1434.
Muro, K. et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann. Oncol. 30, 19–33 (2019).
Wagner, A. D. et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 8, 004064 (2017).
Moreira, A. M. et al. The extracellular matrix: An accomplice in gastric cancer development and progression. Cells 9, 394 (2020).
Yang, Q. et al. Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Anat. Rec. 293, 2012–2019 (2010).
Shah, M. A. et al. Andecaliximab/GS-5745 alone and combined with mFOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma: results from a phase I study. Clin. Cancer Res. 24, 3829–3837 (2018).
Visse, R. & Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ. Res. 92, 827–839 (2003).
Bramhall, S. R. et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: A randomised trial. Br. J. Cancer. 86, 1864–1870 (2002).
Baragaño Raneros, A., Suarez-Álvarez, B. & López-Larrea, C. Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention. Oncoimmunology. 3, e28497 (2014).
Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 141, 52–67 (2010).
Melani, C., Sangaletti, S., Barazzetta, F. M., Werb, Z. & Colombo, M. P. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 67, 11438–11446 (2007).
Liu, L., Ye, Y. & Zhu, X. MMP-9 secreted by tumor associated macrophages promoted gastric cancer metastasis through a PI3K/AKT/Snail pathway. Biomed. Pharmacother. 117, 109096 (2019).
Oliveira, M. J. et al. Helicobacter pylori induces gastric epithelial cell invasion in a c-Met and type IV secretion system-dependent manner. J. Biol. Chem. 281, 34888–34896 (2006).
Kitadai, Y. et al. Helicobacter pylori infection influences expression of genes related to angiogenesis and invasion in human gastric carcinoma cells. Biochem. Biophys. Res. Commun. 311, 809–814 (2003).
Marshall, B. J. & Warren, J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1, 1311–1315 (1984).
Chen, J. et al. Prognostic value of matrix metalloproteinase-9 in gastric cancer: A meta-analysis. Hepatogastroenterology. 61, 518–524 (2014).
Jia, X., Lu, M., Rui, C. & Xiao, Y. Consensus-expressed CXCL8 and MMP9 identified by meta-analyzed perineural invasion gene signature in gastric cancer microarray data. Front. Genet. 10, 851 (2019).
Yao, Z. et al. MMP-2 together with MMP-9 overexpression correlated with lymph node metastasis and poor prognosis in early gastric carcinoma. Tumour Biol. 39, 1010428317700411 (2017).
Wroblewski, L. E., Pritchard, D. M., Carter, S. & Varro, A. Gastrin-stimulated gastric epithelial cell invasion: The role and mechanism of increased matrix metalloproteinase 9 expression. Biochem. J. 365, 873–879 (2002).
Chang, X. et al. NDRG1 controls gastric cancer migration and invasion through regulating MMP-9. Pathol. Oncol. Res. 22, 789–796 (2016).
Marshall, D. C. et al. Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer. PLoS ONE 10, e0127063 (2015).
Koizumi, W. et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 9, 215–221 (2008).
Yamada, Y. et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann. Oncol. 26, 141–148 (2015).
Lee, K. W. et al. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). Gastric Cancer 24, 156–167 (2021).
U.S. Department of Health and Human Services. National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. (2010). https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5×11.pdf.
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228–247 (2009).
Yamaguchi, K. et al. Phase 1b study of andecaliximab (GS-5745, ADX) as monotherapy and in combination with nivolumab (nivo) in Japanese subjects with gastric or GEJ adenocarcinoma. J. Clin. Oncol. 37, 137–137 (2019).
Yoshikawa, A. K. et al. Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: A phase 1b study. J. Immunother. Cancer. 10, e003518 (2022).
JGC Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 24, 1–21 (2021).
Boku, N. et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 10, 1063–1069 (2009).
Cunningham, D. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36–46 (2008).
Shah, M. A. et al. Phase III study to evaluate efficacy and safety of andecaliximab with mFOLFOX6 as first-line treatment in patients with advanced gastric or GEJ adenocarcinoma (GAMMA-1). J. Clin. Oncol. 39, 990–1000 (2021).
Catenacci, D. V. T. et al. FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). J. Clin. Oncol. 39, 4010–4010 (2021).
Ooki, A. & Yamaguchi, K. The dawn of precision medicine in diffuse-type gastric cancer. Ther. Adv. Med. Oncol. 14, 17588359221083048 (2022).
Zhao, R. et al. Vascular endothelial growth factor (VEGF) enhances gastric carcinoma invasiveness via integrin alpha(v)beta6. Cancer Lett. 287, 150–156 (2010).
Shao, L. et al. MMP-9-cleaved osteopontin isoform mediates tumor immune escape by inducing expansion of myeloid-derived suppressor cells. Biochem. Biophys. Res. Commun. 493, 1478–1484 (2017).
Heissig, B. et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109, 625–637 (2002).
Denney, H., Clench, M. R. & Woodroofe, M. N. Cleavage of chemokines CCL2 and CXCL10 by matrix metalloproteinases-2 and -9: Implications for chemotaxis. Biochem. Biophys. Res. Commun. 382, 341–347 (2009).
Shah, M. A. et al. Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival. J. Immunother. Cancer. 9, 1–10 (2021).
Kang, Y. K. et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 234–247 (2022).
Chen, S. Z. et al. Expression levels of matrix metalloproteinase-9 in human gastric carcinoma. Oncol. Lett. 9, 915–919 (2015).
Redondo-Muñoz, J. et al. Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 112, 169–178 (2008).
Takaishi, S. et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 27, 1006–1020 (2009).
Ishimoto, T. et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19, 387–400 (2011).
Yosef, G., Hayun, H. & Papo, N. Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy. Biochem. J. 478, 1139–1157 (2021).
Alford, V. M. et al. Targeting the hemopexin-like domain of latent matrix metalloproteinase-9 (proMMP-9) with a small molecule inhibitor prevents the formation of focal adhesion junctions. ACS Chem. Biol. 12, 2788–2803 (2017).